PharmaFocus Today – Page 27 – media

sell right, sell well, and sell for a long time

First, the essence of business is market competition, and the market is the battlefield. Business people should have a sales mindset, and salespeople need to have a business perspective. There is a view that sales and business are different positions in pharmaceutical companies, with different responsibilities and assessment standards, and it is difficult to integrate the two positions, so you can focus on your own duties. However, the performance appraisal of most pharmaceutical companies is still stuck in the “butt determines the head” standard, and there is rarely a global vision of “the head decides the butt”. It is beneficial for sales and business to empathize, but it cannot completely resolve all conflicts and disputes. At the time of the transformation of the pharmaceutical industry, cross-disciplinary talents who are both proficient in sales and business are increasingly becoming valuable resources for enterprises to compete for. The business position in the ...
- Source: drugdu
- 86
- October 5, 2024
Digital therapeutics are a big failure

The digital therapeutics industry has evolved and evolved beyond all expectations. In June 2021, Pear Therapeutics, the “first stock of digital therapeutics”, was listed; In April 2023, he filed for bankruptcy and bankruptcy; A year later, Better Therapeutics, another star digital therapeutics company, also fell; Four months ago, Akili chose to sell himself and delist and go private. So far, the three musketeers of overseas digital therapeutics have all fallen. If you count from the listing of Pear, a three-year cycle, the waves will sweep away the heroes. On the surface, the main reason for the collapse of these companies is financial problems, but the deeper reason is the commercialization challenges faced by digital therapeutics. The challenge is that digital therapeutics need to have drug-like efficacy in order to gain market acceptance, but the embarrassment is that prescription digital therapeutics are not drugs per se, but more about using technical ...
- Source: drugdu
- 66
- October 5, 2024
The China Securities Regulatory Commission encourages cross-border mergers and acquisitions of unprofitable assets, and a new path for Biotech to land in the capital market?

Wu Qing, chairman of the China Securities Regulatory Commission, said at a press conference of the State Council that in order to further stimulate the vitality of the M&A and restructuring market, the CSRC has studied and formulated the “Opinions on Deepening the Reform of the M&A and Restructuring Market of Listed Companies” (“M&A Six”, hereinafter referred to as the “Opinions”), including supporting the transformation and upgrading of listed companies in the direction of new quality productivity, encouraging industrial integration, improving regulatory tolerance, and improving the transaction efficiency of the restructuring market. Among them, it is clear that it will vigorously support listed companies to carry out cross-industry mergers and acquisitions and acquisitions of unprofitable assets based on transformation and upgrading. This means that unprofitable biotech companies may usher in a new path to land in the capital market. At the meeting, Wu Qing said that mergers and acquisitions are ...
- Source: drugdu
- 77
- October 5, 2024
Medtronic, new progress in ECMO

On September 26, Medtronic’s official website announced the launch of a new ECMO system called VitalFlow™. This is a configurable single-system ECMO solution built on simplicity and performance. According to the official website, the VitalFlow system has a large, intuitive touch screen that centrally displays real-time performance data, provides configurability, and uses the proven Medtronic Nautilus™ ECMO oxygenator design to achieve long-term stable performance. Medtronic said that the VitalFlow™ ECMO system bridges the gap between bedside care and in-hospital transportation, providing clinicians with an easier and smarter ECMO experience. Dr. Karim Bandali, president of the cardiac surgery business within the Medtronic cardiovascular product portfolio, believes that the VitalFlow system is simple and easy to use, allowing users with different comfort levels to serve patients confidently and efficiently. It can be easily moved between different departments of the hospital and has durable and reliable performance. In March 2024, Medtronic completed ...
- Source: https://mp.weixin.qq.com
- 105
- October 4, 2024
To build China’s own blood brand

In recent years, China’s blood gas analyzer market has shown a strong development trend, especially in critical illness, emergency and surgical scenarios, and the scale has expanded dramatically. At present, the market size of blood gas analysis in China is about 2.7 billion yuan, and the industry growth rate is about 20%. From the perspective of market share, imported brands have the first-mover advantage in R&D and market, according to the data reported by the China Research Institute of Puhua Industry Research Institute, about 80% of the current market share of the domestic blood gas analyzer market is still occupied by imported brands, mainly for Radiometer, Wolfen, Abbott, etc., and domestic brands are mainly represented by the head brand of blood gas. According to the statistics of the bidding network, in the first half of 2024, the scale and demand for blood gas equipment procurement across the country ...
- Source: https://mp.weixin.qq.com
- 94
- October 4, 2024
Optimization strategy for production process of RNA targeted drugs

RNA targeted drugs are a completely new category of drugs that are completely different from small molecule drugs and antibody drugs. On the one hand, they can target mRNA, ncRNA, and other intracellular proteins through gene silencing to inhibit their expression and achieve the goal of treating diseases; On the other hand, new generation vaccines and protein replacement therapies can also be developed based on mRNA. RNA targeted drugs are undoubtedly a strategic frontier in biopharmaceutical innovation, with broad potential application scenarios in the future. The production process technology of mRNA industrialization is particularly important for the widespread application and industrialization of mRNA. Based on this, this article will focus on the optimization strategies for the production process of RNA targeted drugs. Stability chemical modification enhances drug safety and efficacy For RNA targeted drugs, chemical modification (excluding tissue targeting ligands) mainly has two basic functions: firstly, chemical modification can significantly ...
- Source: drugdu
- 102
- October 3, 2024
Seven domestic companies have completed a new round of financing, focusing on the fields of cell and gene therapy

In September, several domestic companies focused on the field of cell and gene therapy (CGT) announced progress in financing. This article will share basic information about its 7 companies based on publicly available materials. Xingsairui has successfully completed tens of millions of yuan in angel round financing On September 14th, Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (hereinafter referred to as “Xingsai Ruizhen”) announced the completion of tens of millions of yuan in angel round financing and officially launched the angel+round financing plan! This round of financing is jointly invested by Fosun Pharma’s Rehabilitation Capital New Drug Innovation Fund and Chuangrui Investment Jiaxing Chuangyan Fund. This round of financing will be used for the continuous promotion of core pipelines and platforms, as well as the construction of the company’s team and research and development laboratories. Xingsai Ruizhen was founded in July 2022 and incubated by the New Drug Innovation ...
- Source: drugdu
- 112
- October 3, 2024
Record-breaking advance payments for going overseas, and new changes in breast cancer

Since the discovery of cyclin-dependent kinases (CDKs), scientists have been trying to target them to disrupt cancer cell division and proliferation. Breast cancer in particular relies on this process to grow. Because of this, the first-generation CDK inhibitors targeting CDK4 and CDK6 have been very successful. In February 2015, palbociclib, the first CDK4/6 inhibitor developed by Pfizer, was approved for marketing in the United States for the treatment of locally advanced or metastatic breast cancer of HR/HER2-. There are many breast cancer patients, and in 2020, there were more than 2.3 million new breast cancer patients in the world, making it the world’s largest cancer type. Based on the large patient size, the sales scale of palbociclib is also considerable. In 2016, the sales of palbociclib in the first full year of marketing reached 2.135 billion US dollars, becoming a well-deserved blockbuster drug. Since then, CDK4/6 inhibitors of Eli ...
- Source: https://mp.weixin.qq.com
- 103
- October 3, 2024
“The leader of narcotics” in China, the actual controller may change hands

On September 25, Humanwell Pharmaceutical announced that it had received a “Notification Letter on the Company’s Application for Reorganization” from Wuhan Contemporary Technology Industry Group Co., Ltd. (hereinafter referred to as “Modern Technology”), the controlling shareholder of the company, the day before, and Wuhan Credit Risk Management Financing Guarantee Co., Ltd. and Tianjin Shengcao Law Firm had applied to the Intermediate People’s Court of Wuhan City, Hubei Province for the reorganization of Modern Technology. At present, Humanwell Pharma has not received the documents of the Wuhan Intermediate People’s Court on the acceptance of the above-mentioned application for reorganization, and it is not yet known whether the court will accept it and whether Modern Technology will enter the reorganization procedure in the future. In this regard, many investors took the lead in voting in favor, believing that the replacement of the major shareholder of Modern Technology will be more conducive to ...
- Source: https://mp.weixin.qq.com
- 99
- October 3, 2024
Over 3 billion, Stone Pharmaceutical Group reached a major cooperation

On September 29, Shi Pharma Group signed an exclusive licensing agreement with Jiangsu Conri Pharma on the development and commercialization of JSKN003 in mainland China. JSKN003 is a HER2-targeting bispecific antibody-drug conjugate (ADC) with dual HER2 targeting, giving it stronger internalization induction and bystander killing effects, making it highly active against HER2-expressing tumors. Currently, JSKN003 is undergoing Phase I clinical trials in Australia and Phase I/II and Phase III clinical trials in China. Next, Jinmant Bio (a wholly-owned subsidiary of Chiatai Tianqing Pharmaceutical Group) will be granted exclusive license and sublicensing rights for the development, sales, promised sales, and commercialization of the product. They will bear all clinical development costs and become the sole marketing authorization holder for JSKN003 in Mainland China for that field. According to the agreement, Corning Jerry has the right to receive a total of up to 3.08 billion RMB in upfront and milestone payments, including ...
- Source: https://mp.weixin.qq.com
- 98
- October 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.